Last reviewed · How we verify

Standard heart failure therapy

Nara Medical University · FDA-approved active Small molecule

Standard heart failure therapy typically refers to a combination of ACE inhibitors, beta-blockers, and diuretics that reduce cardiac workload, improve contractility, and manage fluid retention.

Standard heart failure therapy typically refers to a combination of ACE inhibitors, beta-blockers, and diuretics that reduce cardiac workload, improve contractility, and manage fluid retention. Used for Heart failure with reduced ejection fraction (HFrEF), Heart failure with preserved ejection fraction (HFpEF), Symptomatic heart failure.

At a glance

Generic nameStandard heart failure therapy
SponsorNara Medical University
ModalitySmall molecule
Therapeutic areaCardiovascular
PhaseFDA-approved

Mechanism of action

Standard heart failure therapy encompasses multiple drug classes working synergistically: ACE inhibitors reduce afterload and prevent ventricular remodeling, beta-blockers decrease heart rate and contractility to reduce oxygen demand, and diuretics manage fluid overload. This combination approach has been the cornerstone of heart failure management for decades, improving survival and symptom relief.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results